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Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is a common disease with significant health and economic
consequences. This study assesses the burden of COPD in the general population, and the influence of exacerbations (E-
COPD) on disease progression and costs.
Methods: This is a secondary data analysis of healthcare administrative databases of the region of Lombardy, in northern
Italy. The study included $ 40 year-old patients hospitalized for a severe E-COPD (index event) during 2006. Patients were
classified in relation to the number and type of E-COPD experienced in a three-year pre-index period. Subjects were
followed up until December 31st, 2009, collecting data on healthcare resource use and vital status.
Results: 15857 patients were enrolled –9911 males, mean age: 76 years (SD 10). Over a mean follow-up time of 2.4 years
(1.36), 81% of patients had at least one E-COPD with an annual rate of 3.2 exacerbations per person-year and an all-cause
mortality of 47%. A history of exacerbation influenced the occurrence of new E-COPD and mortality after discharge for an E-
COPD. On average, the healthcare system spent 6725J per year per person (95%CI 6590–6863). Occurrence and type of
exacerbations drove the direct healthcare cost. Less than one quarter of patients presented claims for pulmonary function
tests.
Conclusions: COPD imposes a substantial burden on healthcare systems, mainly attributable to the type and occurrence of
E-COPD, or in other words, to the exacerbator phenotypes. A more tailored approach to the management of COPD patients
is required.
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Chronic obstructive pulmonary disease (COPD) is a common
disorder with significant health and economic consequences which
will remain a challenge for the future. [1] It is a major cause of
chronic morbidity and mortality worldwide and by 2030, is
projected to be the third leading cause of death and rank seventh
as burden of disease. [2,3].
The natural course of COPD is affected by exacerbations (E-
COPD), the definition and classification of which are a source of
controversy, but for the purposes of health economics research,
one of the earlier consensus definitions works well. Based on
healthcare utilization, an E-COPD can be classified as follows:
mild, when the patient experiences a worsening of respiratory
symptoms which can be self-treated by increasing the usual
medication; moderate, when the patient needs extra medication,
namely systemic steroids and/or antibiotics; and severe, when the
patient/caregiver is aware of an evident and/or rapid deteriora-
tion in condition, requiring hospitalization. [4] Exacerbations
become more frequent and severe as COPD progresses, though it
has recently been proved that exacerbation rates appear to reflect
a susceptibility phenotype regardless of disease severity, the
frequent exacerbator phenotype. [5,6] E-COPD, particularly the
severe forms, can have serious consequences on the patient’s
quality of life, lung function, and life expectancy, as well as
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significantly increasing the burden in terms of health services and
costs attributable to the disease. [7].
Most cost-of-illness analyses show that costs increase substan-
tially with disease severity, and that a significant proportion of the
economic burden of COPD can be attributed to exacerbations.[8–
11] However, few studies have assessed the economic and social
burden in relation to the type of E-COPD. [9] Moreover, data
based on administrative healthcare databases about the frequency
of exacerbations and the influence of multiple exacerbations on
the clinical and economic burden of COPD are sparse in
literature. [12,13].
Our study provides an updated estimate of the COPD
healthcare burden with regard to Italy and evaluates the existence
of exacerbator phenotypes and its influence, both on the natural
history of the disease and on healthcare cost in patients
hospitalized for COPD in the general population.
Materials and Methods
Ethics Statement
We used administrative healthcare databases in the data
warehouse (DWH) DENALI through a data sharing agreement
with D.G. Sanita` Regione Lombardia. Ethical consent was not
required as this study was a secondary analysis of administrative
anonymous information and data were analyzed anonymously.
Study design and study population
This was a secondary analysis of the DWH DENALI, that
organizes the various administrative databases of the publicly
funded national healthcare system in Lombardy, a region in
northern Italy numbering about ten million inhabitants. DENALI
includes data regarding vital status, hospital discharges, pharma-
ceutical, and outpatient claims in the general population resident
in Lombardy (Appendix S1– Section A).
Individuals $ 40 years old and covered by the regional health
system of Lombardy who were hospitalized for a severe E-COPD
from 1st January to 31st December 2006 were included. The first
severe E-COPD registered during the one-year inclusion period
was the index event and the day of admission to hospital was the
date of entry in the study. Individuals were subsequently followed
up until December 31st, 2009 or until death or migration outside
Lombardy. Data regarding drug prescriptions, hospitalizations,
and outpatient claims were extracted for each patient.
Definition of E-COPD
E-COPD was defined as an event leading either to patients
using antibiotics or corticosteroids or determining their hospital-
ization. The following algorithm was adopted to identify
exacerbations in a three-year pre-index period and during
follow-up.
A severe E-COPD was identified as hospitalization with a
primary discharge diagnosis of COPD (international classification
of diseases, ICD-9-CM, 491.2) or with a primary diagnosis of
pneumonia (480–486), respiratory failure (518.8), pneumothorax
(512.0, 512.8), heart failure (428), or severe pulmonary heart
disease (415) in presence of a secondary diagnosis of COPD.
Subsequent hospitalizations of the same patient were counted as
one acute episode if they occurred within seven days after
discharge. The E-COPD was considered as starting on the date of
the first admission to hospital and ending on the discharge date of
the last one. A moderate exacerbation was identified as
prescription of respiratory antibiotics or corticosteroids used in
the management of acute worsening of COPD symptoms
(Appendix S1– Section B). Subsequent medications prescribed to
the same individual accounted for one moderate E-COPD. Once
moderate and severe exacerbations were separately defined,
presence of a possible overlap between a moderate and a severe
E-COPD was checked for. When treatment periods overlapped,
two E-COPD were put together as one severe E-COPD, starting
when the first one began and finishing when the second one
ended. The same approach was used if less than seven days
elapsed between the end of the previous E-COPD and the
beginning of the following one.
Baseline measurement and study groups
Comorbidities and Charlson index were computed at index
event, based on the discharge diagnoses (ICD-9-CM) reported in
all the hospitalizations registered in the pre-index period and in
the index event. [14,15] The study population was classified
according to the number and type of E-COPD occurring over a
three-year period before the index event. Three groups of patients
were identified: those who had at least one severe E-COPD before
the index event (Group A), those who had only moderate E-
COPD (Group B) and those who did not have any E-COPD
(Group C).
Outcomes
The primary outcomes analysed during follow-up were all-cause
mortality extracted from vital status records and E-COPD.
Mortality at index event was defined as death occurring for any
reason either during the relative hospitalization or within seven
days after hospital discharge.
Healthcare costs and resources use
Healthcare costs (J) in the follow-up were analysed from the
perspective of the Italian National Health Service. Costs were
quantified using charges, i.e. the amount of money the health
system reimbursed to providers of care. Healthcare resources were
divided into three main cost categories: hospitalizations, prescrip-
tions of drugs and outpatient claims. For each category, the cost of
resources connected to the management of COPD was highlight-
ed. Hospital discharges were divided into hospitalizations for E-
COPD and for other reasons. Prescriptions were divided into:
antibiotics or corticosteroids used in the treatment of exacerba-
tions, drugs for obstructive airway diseases, cardiovascular, and
other treatments. Outpatient use of resources was split into three
categories: diagnostic tests usually performed in COPD patients
(pulmonary function tests, respiratory pattern examinations, 6-
minute walking test, chest computed tomography or radiography,
C-reactive protein and sputum examination), all the other
diagnostic tests, and check-ups and general visits. A further
detailed analysis was performed on pulmonary function tests,
including: spirometry and lung volumes, body plethysmography,
diffusion capacity, bronchial provocation, and reversibility testing.
Statistical analysis
The statistical significance of differences among groups was
tested adjusting for age and gender with the Cochran-Mantel-
Haenszel test for categorical variables, ANOVA for continuous
variables and Poisson regression for counting processes. The
Kruskal-Wallis test was used to test differences in the mean follow-
up time. The chosen significance level was 0,05 and Bonferroni
correction was used for multiple comparisons.
The survival and the probability of having an E-COPD during
the follow-up period were described using Kaplan Meier curves.
Difference among groups was tested using Log-rank and the
Wilcoxon test. We computed the rate of total severe plus moderate
Burden of COPD Exacerbations
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E-COPD, and of severe and moderate E-COPD taken separately,
during follow-up, adjusting for age and gender. Rates are
expressed per one person-year and confidence intervals (CI) were
computed using Normal approximation. The impact of number
and type of exacerbations experienced on mortality risk was
analysed using a Cox model with death as the dependent variable,
the number of severe and moderate E-COPDs as two time-
dependent covariates, and age, gender, co-morbidities (Charlson
index) and history of E-COPD as fixed covariates.
Cost of healthcare resources is reported as annual mean per
person. In the estimation of the annual means we needed to
account for right censoring, due to the fact that several patients left
the cohort before the follow-up period was completed. Therefore,
the Bang and Tsiatis partitioned estimator was used. [16]
Confidence intervals for the estimates were calculated using the
bootstrap method with 100 iterations.
Results
Study population
A total of 15857 patients –9911 males; mean (SD) age: 76 (10)
years - who were hospitalized for an E-COPD (index event) during
2006 was identified. Among those, 36% belonged to group A, 53%
to group B and 11% to group C (Table 1). At index event, the
mean age did not vary in relation to history of E-COPD.
Prevalence of men was lower in absence of history of E-COPD
(group C) and it increased in case of history of severe E-COPD
(Group A) versus only moderate E-COPD. Patients without E-
COPD in the pre-index period (group C) had better clinical
conditions: the Charlson index mean, as well as the prevalence of
some of the comorbidities, were significantly lower than in groups
A and B.
Study outcomes
During a mean (SD) follow-up time of 29 (16) months, 47% of
subjects died with a higher percentage of deaths in presence of
history of E-COPD and of severe type (Table 2). At index event
mortality was 5% with no differences among groups. Individuals
with a history of severe E-COPD had the lowest probability of
surviving and patients without a history of exacerbation had the
highest one (Figure 1).
Patients in group A were more likely to experience a new E-
COPD in the follow-up, in particular a severe one, than patients in
groups B and C (Table 2). Moreover, patients in groups C were
least likely to have moderate E- COPD. The probability of having
a new E-COPD was 75% at one year from index event in the
entire population, it increased to 92% at three years (Figure 2).
The probability of experiencing a new E-COPD was higher in
presence of a history of E-COPD at any time of follow-up: it was
significantly highest in group A, then groups B and C followed in
decreasing sequence. After the index event a patient had on
average three E-COPD per year, of which less than one were
severe and the remainders were moderate(Table 2). Patients in
group A had the highest rate of both moderate and severe E-
COPD and group B had higher rates than group C.
The effect of E-COPD, in terms of number and type, on the
mortality risk is depicted in Figure 3. Mortality risk significantly
raised in relation to increasing number of E-COPD experienced
during the follow-up period. Moreover, the severity of the E-
COPD significantly affected mortality risk.
Cost and use of healthcare resources
The mean hospital cost for the index event in 2006 was 3985J
(95%CI 3913–4054) and it was highest in group A. The mean
(95%CI) annual healthcare cost per patient in the follow-up was
6725J (6590–6863), of which 71% was due to hospitalizations,
19% to prescriptions and 10% to outpatient visits and exams
(Table 3). The direct medical cost related to COPD management
amounted to 34% of the total cost. In detail the health system
spent yearly 1705J (1653–1764) per patient for hospitalized E-
COPD, 48J (47–49) for antibiotics or corticosteroids specific for
the treatment of E-COPD, 496J (487–507) for drugs for
Table 1. Main characteristics of the population at index event in relation to the three study groups.
Study population Group A Group B Group C
N (%’) 15857 5625 (36) 8436 (53) 1796 (11)
N. of Male (%) 9911 (63) 3780 (67) 5130 (61)1 1001 (56)12
Age - mean (SD) 76 (9.66) 75 (8.74) 76 (9.90) 76 (11.13)
Comorbidities’’, N (%)
Congestive Heart Failure 4889 (31) 1903 (34) 2474 (30)1 512 (29)1
Diabetes 3068 (17) 1230 (22) 1545 (18)1 293 (16)1
Cerebrovascular disease 2614 (17) 918 (16) 1384 (16) 312 (17)
Renal Disease 1722 (11) 672 (12) 906 (11)1 144 (8)12
Any malignancy 1959 (11) 620 (11) 930 (11) 109 (6)12
Peripheral Vascular Disease 1405 (9) 580 (10) 714 (9)1 111 (6)12
Myocardial Infarction 1253 (8) 456 (8) 674 (8) 123 (7)
Mild Liver Disease 115 (7) 469 (8) 537 (6)1 109 (6)1
Dementia 629 (4) 177 (3) 350 (4) 102 (6)12
Charlson Index’’ - mean (SD) 1.6 (1.97) 1.7 (1.93) 1.7 (2.06) 1.3 (1.62) 12
Group A: patients with at least one severe exacerbation of chronic obstructive pulmonary disease (E-COPD)in the three-year pre-index period; Group B: patients with
only moderate E-COPD in the three-year pre-index period; Group C patients without E-COPD in the three-year pre-index period.SD = standard deviation.
’ % of the whole population.
’’ COPD is not considered as a comorbidity.
1p,0.05 vs group A, 2 p,0.05 vs group B.
doi:10.1371/journal.pone.0101228.t001
Burden of COPD Exacerbations
PLOS ONE | www.plosone.org 3 June 2014 | Volume 9 | Issue 6 | e101228
obstructive airway disease and 38J (37–39) for outpatient
diagnostics. In the breakdown of the total expense related to
COPD treatment (hospitalization with a diagnosis of COPD,
drugs for E-COPD, respiratory drugs and diagnostics for COPD,
hospitalizations continued to account for more than 70%, the
portion related to pharmaceutical increased to 24%, while
outpatient diagnostics accounted for only 2%.
Patients in group A showed the significantly highest total
healthcare cost per patient and patients in group B had higher per
patient cost than patients in group C. Differences between groups
A and B in the per patient cost were mainly attributable to
differences in the expense due to hospitalizations for E-COPD and
prescriptions of drugs related to COPD treatment, as well as
diagnostics for COPD and general visits, while differences between
group C and the other two groups were detected in all cost
categories.
Up to 75% of the study population didn’t present any claim for
pulmonary function tests at the end of follow-up, with differences
among groups: the percentage of patients without exam was
highest in group C and it was lowest in group B (Table 4). The
Figure 1. Probability of survival during follow-up in relation to the three study groups. Group A: patients with at least one severe
exacerbation of chronic obstructive pulmonary disease (E-COPD) in the three-year pre-index period; Group B: patients with only moderate E-COPD in
the three-year pre-index period; Group C patients without E-COPD in the three-year pre-index period. Differences between groups are significant (p,
0.05, Log-rank and Wilcoxon tests).
doi:10.1371/journal.pone.0101228.g001
Table 2. Main outcomes of the study population, in relation to the three study groups.
Study population Group A Group B Group C
Follow-up time (months) – mean (SD) 29 (16.31) 29 (16?41) 29 (16.24) 30 (16.29)
Death at index event, N(%) 760 (5) 253 (5) 403 (5) 104(6)
Death, N(%) 7452 (47) 2887 (51) 3826 (45)1 739 (41)12
Total E-COPD
N. of subjects with at least one, N (%) 12856 (81) 4867 (87) 6871 (82)1 1118 (62)12
Annual rate’ (CI 95%) 3.2 (3.15–3.20) 4.3 (4.19–4.31) 2.9 (2.88–2.94) 1.2 (1.13–1.21)
Severe E-COPD
N. of subjects with at least one, N (%) 6878 (43) 3648 (65) 2823 (34)1 407 (23)12
Annual rate’ (CI 95%) 0.5 (0.51–0.53) 0.9 (0.91–0.97) 0.3 (0.30–0.32) 0.2 (0.17–0.20)
Moderate E-COPD
N. of subjects with at least one, N (%) 12045 (76) 4459 (79) 6585 (78) 1001 (56) 12
Annual rate’ (CI 95%) 2.7 (2.64–2.68) 3.3 (3.26–3.36) 2.6 (2.57–2.63) 1.0 (0.95–1.03)
Group A: patients with at least one severe exacerbation of chronic obstructive pulmonary disease (E-COPD) in the three-year pre-index period; Group B: patients with
only moderate E-COPD in the three-year pre-index period; Group C patients without E-COPD in the three-year pre-index period. The index event is not included.
SD= standard deviation.
’Age and sex adjusted rate per one person-year.
1p,0.05 vs group A, 2 p,0.05 vs group B.
doi:10.1371/journal.pone.0101228.t002
Burden of COPD Exacerbations
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mean annual cost per person of pulmonary function testing was
11J (10–11) with a lower cost in group C. The cost didn’t change
by year of follow-up and neither did the percentage of patients
with at least one exam each year, which was about 15% with even
lower values in group C.
Discussion
The present study evaluates the healthcare burden associated
with COPD patients followed for up to three years after discharge
for an episode of E-COPD. It also examines the presence of
subgroups defined by exacerbation phenotypes and their influence
on the progression of disease and healthcare costs. The main
findings of the study are: 1) over a mean follow-up time of 2.4
Figure 2. Probability of having an E-COPD during follow-up in relation to the three study groups. Group A: patients with at least one
severe exacerbation of chronic obstructive pulmonary disease (E-COPD) in the three-year pre-index period; Group B: patients with only moderate E-
COPD in the three-year pre-index period; Group C patients without E-COPD in the three-year pre-index period. Differences between groups are
significant (p,0.05, Log-rank and Wilcoxon tests).
doi:10.1371/journal.pone.0101228.g002
Figure 3. Hazard Ratio of death (HR, 95%CI) by number (N) and type of E-COPD experienced during follow-up. Time-dependent Cox
model adjusted by age, sex, comorbidities (Charlson index) and history of E-COPD in the three-year pre-index period.
doi:10.1371/journal.pone.0101228.g003
Burden of COPD Exacerbations
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years, 81% of patients had at least one moderate or severe E-
COPD with an annual exacerbation rate of 3.2 per person-year
and an all-cause mortality rate of 47%; 2) on average, the health
system spent 6725 J per person per year, 34% of which could be
attributed to COPD management; pulmonary function test was
still underused; 3) the type and history of E-COPD impacted the
occurrence of new E-COPD and mortality as well as healthcare
use and costs during follow-up.
Our data report an high exacerbation rate over a long follow-
up, with an annual rate of 3.2 per one person-year, and of 0.2 for
severe exacerbations. Various authors have estimated the annual
E-COPD rate from a low of 0.5 to a high of 3.5 per patient, but
3.0 per year represents the upper limit reported in literature in
those studies with long-term follow-up. [17,18] This high rate may
also be influenced by the population characteristics, all patients
had at least one hospitalisation for E-COPD. Moreover, we
confirm the existence of exacerbator phenotypes and the
importance of exacerbation history (number and type) in order
to define them. [6,12] Patients with a history of severe E-COPD
are most likely to experience a new E-COPD with the highest
annual exacerbation rate while patients with no history of E-
COPD are least likely to experience new exacerbations with the
minor exacerbation rate. These findings suggest that patients may
not return to the previous stable state after an exacerbation, but
there may be increased airway inflammation, lung function
decline, increased bacterial colonization and thus increased
susceptibility to further exacerbations. [19].
In our population, the probability of death was in line with
mortality figures reported by other studies. [20–22] History of
exacerbations was associated with a higher probability of death
during the follow-up but not with mortality at index event,
confirming a higher risk in relation to exacerbation frequency.
[20] We also found that severe exacerbation history increases
mortality risk. Moreover we found a positive relationship among
mortality and both severity and number of E-COPD experienced
during the follow-up at same history of E-COPD and comorbid-
ities. The impact of occurrence and type of exacerbations on
mortality can be explained by the level of both local and systemic
Table 3. Mean annual cost (J) per person of healthcare resources with 95%CI of the study population.
Study population Group A Group B Group C
Total Healthcare Resources 6725 (6590–6863) 8779 (8547–9005) 5999 (5839–6176) 3968 (3697–4283)
Hospitalizations 4753 (4645–4859) 6658 (6458–6871) 3957 (3819–4095) 2757 (2553–2979)
Diagnosis of E-COPD 1705 (1653–1764) 3268 (3139–3384) 945 (888–1000) 564 (502–651)
Other Diagnoses 3048 (2982–3126) 3390 (3254–3532) 3012 (2905–3117) 2193 (2039–2376)
Prescriptions 1269 (1245–1295) 1469 (1435–1506) 1253 (1212–1289) 756 (707–804)
Drugs for E-COPD’ 48 (47–49) 63 (61–65) 45 (44–47) 16 (15–17)
Respiratory Drugs’’ 496 (487–507) 669 (648–686) 438 (428–452) 253 (229–275)
Cardiovascular Drugs+ 234 (225–243) 218 (205–231) 252 (236–266) 201 (189–215)
Other Drugs 437 (419–453) 434 (413–455) 478 (450–508) 260 (231–292)
Outpatient Visits & Exams 703 (630–784) 652 (551–780) 789 (662–908) 455 (342–600)
Diagnostics for COPD, 38 (37–39) 41 (39–44) 39 (37–40) 24 (22–27)
Other Diagnostics 619 (547–700) 559 (455–686) 705 (578–824) 400 (288–544)
General Visits 46 (45–46) 52 (50–53) 45 (44–46) 31 (29–33)
Group A: patients with at least one severe exacerbation of chronic obstructive pulmonary disease (E-COPD) in the three-year pre-index period; Group B: patients with
only moderate E-COPD in the three-year pre-index period; Group C patients without E-COPD in the three-year pre-index period. The index event is not included.
’Drugs used to treat COPD exacerbation. ’’Drugs for obstructive airway diseases - Anatomical therapeutic Chemical (ATC) Classification R03 -. +Drugs for the
cardiovascular system - ATC C -. ,Pulmonary function tests, respiratory pattern examination, 6-minute walking test, chest computed tomography or radiography, C-
reactive protein and sputum examination.
doi:10.1371/journal.pone.0101228.t003
Table 4. Mean annual cost (J) per person with 95%CI and resource consumption of pulmonary function test.
Study population Group A Group B Group C
N. of subjects with exam in (%)
first year 2412(15) 829 (15) 1391 (17)1 192 (12)12
second year 1822 (15) 683 (16) 1010 (15) 129 (11)12
third year 1497 (14) 556 (16) 835 (14) 106 (9)12
entire follow-up 3904 (25) 1386 (25) 2215 (26)1 303 (17)12
Cost - annual mean (95% CI) 11 (10–11) 12 (11–13) 11 (10–12) 6 (5–7)
It includes spirometry and lung volumes, body plethysmography, diffusion capacity, bronchial provocation and reversibility testing.
Group A: patients with at least one severe exacerbation of chronic obstructive pulmonary disease (E-COPD) in the three-year pre-index period; Group B: patients with
only moderate E-COPD in the three-year pre-index period; Group C patients without E-COPD in the three-year pre-index period.1 p,0.05 vs group A, 2 p,0.05 vs group
B.
doi:10.1371/journal.pone.0101228.t004
Burden of COPD Exacerbations
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inflammation characterizing an E-COPD that can lead to the
development of adverse outcomes, including cardiovascular
events. [23,24].
The mean annual total healthcare cost was 6725J per patient,
34% of which could be attributed to COPD management. In line
with previous studies, the major driver of the direct medical cost in
COPD patients was attributable to hospitalizations. [9,10]
Moreover, we confirm that pulmonary functional test was still
underused, although the relative expense is low. [25,26] On the
other hand, performing spirometry may not be associated with
significant improvement in the management of COPD. [27]
Further studies are thus needed to investigate more closely the role
of spirometry in the follow-up of COPD patients.
The type and frequency of exacerbations affect direct healthcare
costs for society. In our population, patients with history of E-
COPD accounted for a higher mean annual per patient cost than
patients without any history. Moreover, patients with a history of
severe exacerbations had the highest cost. A history of E-COPD
therefore suggests a future frequent exacerbator phenotype, which
leads to higher healthcare costs and use, as recent US studies have
reported. [10,12,28] Furthermore, the healthcare costs increased
in proportion to the severity of E-COPD, since a severe
exacerbation requires hospitalization, at an average cost in our
study of 3985 J, which is consistent with previous data. [29].
The present study has some limitations, mainly inherent to the
use of healthcare administrative data. Although our definition of
E-COPD fails to capture mild exacerbations and may have
included some hospitalization that do not strictly refer to severe E-
COPD (current guidelines definition), it is a recognized classifica-
tion in healthcare economics research. Moreover, the population
in study may underrepresent infrequent exacerbators and no
clinical and functional data were available regarding either
severity of COPD or causes of death. Finally, in our economic
analysis, there were no data available as regards indirect costs, or
costs related to emergency call-outs and general practitioner visits.
Since general practitioners are paid on a capitation basis, the cost
does not change in relation to the illness or the number of visits, so
it is not relevant to economic evaluations. Indirect cost is difficult
to estimate, and few studies have attempted to do so, although it is
well-known that COPD affects quality of life and consequently
leads to production losses, generating a substantial burden. [5]
However, the use of administrative databases does provide a range
of data not necessarily available from other sources with such low
budget efforts. Our study is strengthened by the evaluation of the
COPD burden in a large population outside strict selection criteria
and by a potential follow-up time of at least three-years, a duration
widely accepted as being long enough to capture significant
endpoints.
Conclusions
This study provides updated estimates of direct healthcare costs
in COPD patients beyond their individual characteristics and the
time duration of clinical trials. Secondly, it gives more strength to
the concept of t exacerbator phenotypes, since both the type and
frequency of exacerbations have a substantial impact on the
patient’s quality of life and healthcare resource use and costs. The
main implication of the study is the importance of prevention of
exacerbations as the principal means of providing both clinical
benefit and reducing healthcare cost in COPD patients. A flood of
data shows that pharmacological interventions and vaccinations
are able to significantly improve clinical outcomes. [30,31] An
improvement in COPD management with appropriate therapies,
as well as correct prophylactic measures, would also clearly be
cost-effective for healthcare systems.
Supporting Information
Appendix S1 Supporting information on methods. The
file contains two sections. Section A gives more details on the
structure and content of the data warehouse DENALI. Section B
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